JP Morgan Downgrades Fulcrum Therapeutics to Underweight

Benzinga Newsdesk www.benzinga.com Negative 92.3%

Neg 92.3% Neu 0% Pos 0%

JP Morgan downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight.

Comments

No comments yet. Be the first!